EXEL Key Statistics, Chart & Performance
The current stock price of EXEL is 42.51 USD. In the past month the price increased by 9.79%. In the past year, price increased by 19.38%.
EXEL Latest News, Press Relases and Analysis
EXEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About EXEL
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1147
Phone: 16508377000
EXELIXIS INC / EXEL FAQ
What does EXEL do?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
What is the current price of EXEL stock?
The current stock price of EXEL is 42.51 USD. The price increased by 1.75% in the last trading session.
Does EXEL stock pay dividends?
EXEL does not pay a dividend.
What is the ChartMill rating of EXELIXIS INC stock?
EXEL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the Price/Earnings (PE) ratio of EXELIXIS INC (EXEL)?
The PE ratio for EXELIXIS INC (EXEL) is 17.94. This is based on the reported non-GAAP earnings per share of 2.37 and the current share price of 42.51 USD.
Is EXELIXIS INC (EXEL) expected to grow?
The Revenue of EXELIXIS INC (EXEL) is expected to grow by 7.2% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does EXELIXIS INC (EXEL) report earnings?
EXELIXIS INC (EXEL) will report earnings on 2026-01-12, after the market close.
EXEL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL is one of the better performing stocks in the market, outperforming 84% of all stocks.
EXEL Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to EXEL. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues.
EXEL Financial Highlights
Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.37. The EPS increased by 44.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.63% | ||
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| Debt/Equity | 0 |
EXEL Forecast & Estimates
26 analysts have analysed EXEL and the average price target is 45.9 USD. This implies a price increase of 7.97% is expected in the next year compared to the current price of 42.51.
For the next year, analysts expect an EPS growth of 29.57% and a revenue growth 7.2% for EXEL